Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT

Terminated 88 enrolled Mount Sinai Hospital, Canada Canadian Institutes of Health Research (CIHR) · collab Pfizer · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the livebirth rate of women with recurrent pregnancy loss and autoantibodies randomized to either low molecular weight heparin plus aspirin versus aspirin alone.

Timeline

Start: 2000-03
Primary completion: —
Completion: 2005-09

Outcome

Outcome not reported

Stopped: “interim analysis found no difference in LB rate and lower than expected event rate”

Publications

Hamulyak EN, Scheres LJ, Marijnen MC, Goddijn M, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aspirin	Small molecule	81 mg	—
Subject	Dalteparin sodium	Other / unclassified	5000 iu	Subcutaneous